Bayer Ups Guidance While Pharma Head Highlights NHL Drug Copanlisib
Bayer has initiated the regulatory filing process in the US for its pipeline non-Hodgkin's lymphoma drug copanlisib, head of pharma Dieter Weinand said during the company's first quarter earnings call during which the German group also said it was upping guidance for the year.
You may also be interested in...
Keeping Track Of New Drugs: US FDA Review Queue Adds Spark Gene Therapy, Amgen Migraine Antibody, Bayer Oncologic
The latest news about novel agent applications from our FDA Performance Tracker.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The stereotypical view of an Alzheimer’s patient as an elderly person needs to change and interventions made earlier in the disease course, while we wait for novel drug therapies, said experts at a recent virtual meeting.